Investor Updates

15. März 2010
Roche's First Quarter Sales 2010 Conference Call
Roche will publish its Sales Results for the 1st Quarter of 2010 prior to the opening of the Swiss Stock Exchange on Thursday ... mehr

12. März 2010
Roche provides update on phase III study of Avastin in men with late stage prostate cancer
Roche announced today the topline results of a phase III trial led by the US Cancer and Leukemia Group B (CALGB) and sponsored ... mehr

08. März 2010
Roche and Biogen Idec decide to suspend Ocrelizumab treatment - Rheumatoid Arthritis development programme on hold
Roche and Biogen Idec announced today their decision to suspend Ocrelizumab treatment of patients in the Rheumatoid Arthritis ... mehr

02. März 2010
Roche Annual General Meeting: dividend raised by 20%
Roche's Annual General Meeting, which was held today in Basel, has approved all the Board of Directors' proposals. ... mehr

25. Februar 2010
Avastin phase III study shows positive results in women with advanced ovarian cancer
Roche announced today that a phase III study showed the combination of Avastin (bevacizumab) and chemotherapy followed by ... mehr

24. Februar 2010
European Medicines Agency grants positive opinion for Xeloda in combination with oxaliplatin for the adjuvant treatment of early colon cancer
Roche announced today that Xeloda (capecitabine) in combination with oxaliplatin (a combination known as XELOX) has been recommended ... mehr

23. Februar 2010
Phase III study of Avastin plus chemotherapy in advanced stomach cancer did not meet primary endpoint
Roche announced today the topline results from a global phase III trial investigating the use of Avastin (bevacizumab) in ... mehr

19. Februar 2010
US FDA approves Rituxan/MabThera for the most common type of adult leukemia
Roche announced today that the US Food and Drug Administration (FDA) approved Rituxan/MabThera (rituximab) plus fludarabine ... mehr

03. Februar 2010
Strong operating performance for Roche in 2009
Record sales, double-digit growth in operating profit and Core Earnings per share – Dividend increase by 20% to 6.00 ... mehr

28. Januar 2010
Roche establishes new medical research hub in Singapore
Roche announced today that it will enter into a strategic alliance with Singapore’s scientific and medical institutions ... mehr

28. Januar 2010
Herceptin now approved in the EU for patients with HER2-positive advanced stomach cancer
Roche announced today that the European Commission has approved Herceptin (trastuzumab) in combination with chemotherapy for ... mehr

27. Januar 2010
Reminder: Roche's Full Year Results for 2009
Roche will publish its Full Year Results for 2009 prior to the opening of the Swiss Stock Exchange on February 3 at 7:00 CET ... mehr

11. Januar 2010
FDA approves ACTEMRA for the treatment of moderately to severely active rheumatoid arthritis
First-in-class biologic therapy, IL-6 receptor-inhibiting monoclonal antibody approved based on largest clinical development ... mehr

04. Januar 2010
Roche's Full Year Results for 2009
Roche will publish its Full Year Results for 2009 prior to the opening of the Swiss Stock Exchange on February 3 at 7:00 CET ... mehr

04. Januar 2010
Xeloda in combination with oxaliplatin filed in Europe for the adjuvant treatment of patients with early colon cancer
Roche announced today that it has submitted an application to the European Medicines Agency (EMEA) to extend the label of ... mehr

22. Dezember 2009
Genentech Submits Supplemental Application to FDA for Lucentis in Patients with Retinal Vein Occlusion
Genentech, Inc., a wholly owned member of the Roche Group, today announced that the company submitted a supplemental Biologics ... mehr

18. Dezember 2009
Investor meeting Thursday 18 March 2010 New York
Dr Severin Schwan (CEO Roche Group) and the Roche Investor Relations team would like to invite you to the first Investor meeting ... mehr

18. Dezember 2009
Herceptin receives positive opinion in record time for the treatment of HER2-positive advanced stomach cancer in Europe
Roche announced today that the European Medicines Agency (EMEA) Committee on Human Medicinal Products (CHMP) has issued a ... mehr

17. Dezember 2009
Roche's weekly taspoglutide meets primary end-points in two further head-to-head Phase III clinical trial comparisons with insulin glargine (Lantus) and also versus placebo in patients with high body mass index (BMI)
Taspoglutide demonstrates non-inferiority HbA1c change versus insulin glargine and superiority in HbA1c change versus placebo mehr

14. Dezember 2009
Greater chances of cure for patients with HER2-positive early breast cancer when treated with one year of Herceptin
Roche announced new long-term follow up-data from two large pivotal studies evaluating adjuvant Herceptin in HER2-positive ... mehr

14. Dezember 2009
Early-stage breast cancer study with Avastin (E5103) will resume enrolment and continue as planned
Roche has been informed that the U.S. Food and Drug Administration (FDA) is allowing enrolment to resume into a phase III ... mehr

12. Dezember 2009
New Phase II study showed trastuzumab-DM1 shrank tumours in women with highly advanced HER2-positive breast cancer
Roche today announced positive results from a Phase II study of trastuzumab-DM1 (T-DM1). As assessed by independent review, ... mehr

11. Dezember 2009
Avastin plus commonly used chemotherapies improves time without the disease getting worse in women with previously treated advanced breast cancer
Roche today announced results from a phase III study (RIBBON 2) of Avastin® (bevacizumab) in women with advanced HER2-negative ... mehr

11. Dezember 2009
Roche, Genentech and Biogen Idec announce positive results from first phase III trial of ocrelizumab in rheumatoid arthritis
Roche, Genentech, Inc. a wholly owned member of the Roche Group, and Biogen Idec announced today a Phase III study (STAGE) ... mehr

11. Dezember 2009
Positive interim analysis supports early closure of heart failure trial
Further analysis could promote new paradigm in the management of heart failure. Roche and study investigators at the Massachusetts ... mehr

09. Dezember 2009
Roche Introduces New Automated Clinical Laboratory System for CE-Marked Testing of Human Papillomavirus, Chlamydia and N. gonorrhoeae
Roche Molecular Systems, Inc. announced today the launch of a new clinical laboratory system designed to increase laboratory ... mehr

09. Dezember 2009
Important progress in treatment of early and late stage breast cancer with Herceptin, Avastin and T-DM1
Roche announced today that new 5 year follow-up data from two pivotal studies with Herceptin® (trastuzumab) in early ... mehr

08. Dezember 2009
MabThera/Rituxan is the first treatment to show improved overall survival in previously untreated patients with chronic lymphocytic leukemia
Roche announced today at the 51st Meeting of the American Society of Hematology (ASH) in New Orleans, LA (USA) that the pivotal ... mehr

07. Dezember 2009
Reminder: Invitation to Roche investor science event from SABCS 2009
We kindly invite investors and analysts to participate in a conference call to discuss new clinical data and results presented ... mehr

04. Dezember 2009
Roche reports positive phase II results with ocrelizumab in relapsing-remitting multiple sclerosis (RRMS)
Roche and its development partner Biogen Idec have reported positive phase II data with ocrelizumab, a humanized anti-CD20 ... mehr

04. Dezember 2009
MabThera/Rituxan: promising new data in leukemia and lymphatic cancers to be presented at the American Society of Hematology (ASH), the world's leading meeting in blood cancers
Roche announced today that updated results of the pivotal phase III study, CLL8, will be one of many key presentations at ... mehr

02. Dezember 2009
Results from two further Phase III clinical trials show that Roche’s weekly taspoglutide met its primary end-points in head to head study with sitagliptin (Januvia) and versus placebo
Roche today announced headline results from the second and third of eight T-emerge Phase III studies for taspoglutide. T-emerge ... mehr

01. Dezember 2009
Reminder: Invitation to Roche investor science event from ASH 2009 - Conference call on 8 December 2009
We kindly invite investors and analysts to participate in a conference call to discuss new clinical data and results presented ... mehr

25. November 2009
Avastin filed for broader breast cancer label in Europe for use in combination with standard chemotherapies
Roche announced today that they have filed to extend the current European label of Avastin (bevacizumab) in patients with ... mehr

20. November 2009
European medical advisory committee does not recommend approval of Avastin for deadly form of brain cancer
Roche announced today that the Committee for Medicinal Products for Human Use (CHMP), which is responsible for conducting ... mehr

20. November 2009
ACTEMRA Improves Signs and Symptoms in Children with Systemic Onset Juvenile Idiopathic Arthritis (sJIA)
Roche announced today that ACTEMRA (tocilizumab, known as RoACTEMRA within the EU) successfully met its primary endpoint in ... mehr

18. November 2009
US FDA issues complete response letter for Rituxan/MabThera for chronic lymphocytic leukaemia
Roche announced today that the US Food and Drug Administration (FDA) issued a complete response to Genentech, a wholly-owned ... mehr

18. November 2009
Invitation to Roche investor science event from SABCS 2009
We kindly invite investors and analysts to participate in a conference call to discuss new clinical data and results presented ... mehr

18. November 2009
Roche announces start of new atherosclerosis study (dal-PLAQUE 2) for dalcetrapib
Roche today presented new preclinical data further supporting the differentiation of its novel cholesteryl ester transfer ... mehr

17. November 2009
Applications to allow Avastin to be combined with commonly used chemotherapies in advanced breast cancer submitted to FDA
Roche announced today that Genentech, a wholly-owned member of the Roche Group, has submitted two supplemental Biologics License ... mehr

16. November 2009
FDA Grants Emergency Use Authorization to Roche's Assay for 2009 H1N1 Influenza Virus
Roche announced today that it's RealTime ready Influenza A/H1N1 Detection Set for the 2009 H1N1 influenza virus has received ... mehr

10. November 2009
Roche reports positive Phase II results with potential first-in-class treatment for the negative symptoms of schizophrenia
Roche today reports results from a 320 patient phase II proof-of-concept study with it’s investigational glycine transporter-1 ... mehr

09. November 2009
Invitation to Roche investor science event from ASH 2009 - Conference call on 8 December 2009
mehr

09. November 2009
Anti-Malignancy Agent Avastin Obtained Approval for Additional Indication of Non-Small Cell Lung Cancer
Please find attached a press release issued by Chugai in Japan mehr

29. Oktober 2009
First Phase III clinical trial of Roche`s weekly taspoglutide meets primary end-point of change in HbA1c
Roche today announced that headline results from its Phase III study, T-emerge 2 (subcutaneous weekly taspoglutide versus ... mehr

22. Oktober 2009
Phase III trial underway to investigate infusion-free administration of Herceptin for women with HER2-positive breast cancer
Roche and Halozyme Therapeutics announced today that a new subcutaneous formulation of Herceptin using Halozyme’s Enhanze ... mehr

19. Oktober 2009
Genentech and Biogen Idec Receive a Complete Response from FDA for Earlier Use of Rituxan for Rheumatoid Arthritis
Please find attached a press release issued by Genentech and Biogen Idec in the US with respect to the approval of Rituxan ... mehr

17. Oktober 2009
ACTEMRA inhibits progression of joint destruction in RA patients by over 80% compared to methotrexate alone
Two-year data from the LITHE study, being presented at the American College of Rheumatology, show that, with long-term use, ... mehr

16. Oktober 2009
Anti-Malignancy Agent/Anti-VEGF Humanized Monoclonal Antibody, Avastin Application for Approval of Additional Indication of Breast Cancer
Please find enclosed a press release by Chugai mehr

15. Oktober 2009
Roche reports further accelerated sales growth in third quarter
Group sales up 3.1 billion to 36.4 billion Swiss francs in first nine months, an increase of 11% in local currencies (9% in ... mehr

07. Oktober 2009
Reminder: Roche's Third Quarter Sales 2009 Conference Call
Roche will publish its Sales Results for the 3rd Quarter of 2009 prior to the opening of the Swiss Stock Exchange on Thursday ... mehr

05. Oktober 2009
Two Phase III studies of Lucentis show early and sustained improvement in vision in patients with retinal vein occlusion
Genentech, Inc., a wholly-owned member of the Roche Group yesterday announced results from two Phase III studies of Lucentis® ... mehr

30. September 2009
RoACTEMRA filed in Europe for the Inhibition of Joint Damage and Improvement in Physical Function in Rheumatoid Arthritis
Roche announced today that it has submitted a filing to the European health authorities (the European Medicines Agency) to ... mehr

25. September 2009
Roche provides update on early-stage breast cancer study with Avastin
Roche has been informed by the National Cancer Institute and US Eastern Cooperative Oncology Group (ECOG) that they have suspended ... mehr

24. September 2009
Herceptin provides impressive survival benefit for patients with high levels of HER2 in their stomach cancer
A detailed analysis of the Phase III ToGA study announced today revealed an unprecedented survival benefit for patients whose ... mehr

24. September 2009
Continuous improvements in animal welfare within Roche Research
Roche announced the winners of its global 3Rs Award Program - a unique and innovative program that helps to reduce and limit ... mehr

24. September 2009
Anti-Cancer Agent Xeloda and Avastin Obtained Approval for Additional Indication of Colorectal Cancer
Please find enclosed a press release by Chugai mehr

23. September 2009
Adding Xeloda to standard chemotherapy before surgery helps to eradicate tumours in patients with early breast cancer
Results from the ABCSG 24 trial presented today at the joint 15th ECCO and 34th ESMO 2009 congress, Berlin, Germany showed ... mehr

23. September 2009
From inoperable disease to potentially life saving surgery - new Avastin data gives hope to colorectal cancer patients with liver metastases
New data from several studies presented at ECCO 151 and ESMO 342 confirm unique benefits of Avastin (bevacizumab) and Xeloda ... mehr

23. September 2009
Roche announces results from two early studies which show promise for patients with malignant melanoma
New data from phase II Avastin study and a phase I extension study of highly selective BRAF inhibitor mehr

23. September 2009
Phase IV lung cancer study confirms the safety and outstanding efficacy benefit of Avastin-based therapy in a 'real world' setting.
Key data from four presentations at the joint ECCO 15 and ESMO 34 congress strongly support the clinical benefit of Avastin ... mehr

21. September 2009
Reminder: Roche Investor Science Event: Conference Call from ECCO ESMO 2009 - Friday, September 25th, 2009
We are pleased to invite you to a Conference Call to discuss new data on Roche’s oncology products and pipeline being ... mehr

18. September 2009
Antineoplastic Agent / Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, Tarceva
Application for Approval of Additional Indication of Pancreatic Cancer mehr

17. September 2009
Study shows MabThera maintenance treatment delays disease progression in patients with incurable lymphoma
Results show patients treated with MabThera as initial and follow-on therapy stay in remission for longer. Roche announced ... mehr

14. September 2009
Roche's Third Quarter Sales 2009 Conference Call
Roche will publish its Sales Results for the 3rd Quarter of 2009 prior to the opening of the Swiss Stock Exchange on Thursday ... mehr

13. September 2009
Two new studies report increased survival rates in Tamiflu-treated patients with avian flu (H5N1) and severe seasonal flu
53% of patients with H5N1 infection survived when treated with Tamiflu compared with 12% of untreated patients. Rate of death ... mehr

11. September 2009
Roche Investor Science Event: Conference Call from ECCO ESMO 2009 - Friday, September 25th, 2009
We are pleased to invite you to a Conference Call to discuss new data on Roche’s oncology products and pipeline being ... mehr

08. September 2009
Roche announces new Corporate Executive Committee
William M. Burns, Juergen Schwiezer and Jonathan Knowles to retire – Pascal Soriot appointed COO Pharma Division and ... mehr

03. September 2009
Roche recognised as new Super Sector Leader in Dow Jones Sustainability Index
Roche (SIX: RO, ROG; OTCQX: RHHBY) has been rated as the new Super Sector Leader in Healthcare on the Dow Jones Sustainability ... mehr

03. September 2009
MabThera approved in Europe for use in patients with previously-treated chronic lymphocytic leukaemia
Roche announced today that the European Commission has approved MabThera (rituximab) for use in patients with relapsed or ... mehr

01. September 2009
Roche receives CE Mark certification for cobas 8000 modular analyzer series
Roche announced today that the CE Mark certification for cobas 8000 modular analyzer series has been granted allowing commercial ... mehr

31. August 2009
FDA Approves Valcyte (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants
Plus new oral solution offers dosing flexibility for pediatric patients. Roche announced today that the U.S. Food and Drug ... mehr

31. August 2009
Roche and Lonza Announce Opt-in for Singapore Manufacturing Facility
Roche and Lonza announced today that Genentech Singapore Pte. Ltd. (“Genentech Singapore”), a wholly-owned member ... mehr

18. August 2009
Avastin plus commonly used chemotherapies improves time without the disease getting worse in women with previously treated advanced breast cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a Phase III study of Avastin (bevacizumab) in combination with a range ... mehr

05. August 2009
Roche Continents takes place for the third time
For the third time, Roche and the Salzburg Festival have invited 100 students to take part in "Roche Continents". ... mehr

03. August 2009
Avastin approved in US for the most common type of kidney cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin (bevacizumab) plus interferon ... mehr

01. August 2009
Phase III study showed Tarceva helped patients with advanced non-small cell lung cancer live longer when used immediately after initial chemotherapy
Roche today announced that patients with advanced non-small cell lung cancer (NSCLC) who received Tarceva (erlotinib) immediately ... mehr

31. Juli 2009
FDA accepts complete response resubmission for ACTEMRA (tocilizumab)
Roche announced today that the U.S. Food & Drug Administration (FDA) has accepted the resubmission for the ACTEMRA (tocilizumab) ... mehr

30. Juli 2009
Second Phase III Study Showed Lucentis Improved Vision in Patients with Retinal Vein Occlusion
Roche announced today that the Phase III study CRUISE showed Lucentis (ranibizumab injection) improved vision in patients ... mehr

29. Juli 2009
European commission approves broader label for Avastin allowing combination with docetaxel for the first-line treatment of advanced (metastatic) breast cancer
More patients with advanced breast cancer could benefit from Avastin as a result of a broader label allowing Avastin to be ... mehr

28. Juli 2009
Genentech Announces Appointment of Sandra J. Horning, M.D., to Senior Vice President, Global Head, Clinical Development Hematology/Oncology
Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the appointment of ... mehr

28. Juli 2009
Roche and Google.org Start Initiative for Early Discovery of New Diseases
Roche Applied Science and Google.org recently started a joint project to demonstrate the feasibility of developing a multidisciplinary ... mehr

24. Juli 2009
MabThera receives positive opinion in Europe for treating patients whose chronic lymphocytic leukaemia returns
Roche announced today that the European Union’s Committee on Human Medicinal Products (CHMP) has issued a positive recommendation ... mehr

24. Juli 2009
Full reconciliation of Chugai interim results into IFRS
Following the publication of Chugai’s official 2009 interim results, Roche offers this investor update which reconciles ... mehr

23. Juli 2009
Double-digit increase in sales, operating profit and Core EPS
Integration of Genentech progressing rapidly; full-year outlook raised; Group sales up 2 billion to 24 billion Swiss francs, ... mehr

22. Juli 2009
Reminder: Roche's Half Year Results for 2009
Roche will publish its Half Year Results for 2009 prior to the opening of the Swiss Stock Exchange on July 23 at 7.00 CET ... mehr

22. Juli 2009
Chugai Files NDA for a Renal Anemia Agent R744
Please find enclosed a press release by Chugai. mehr

21. Juli 2009
Roche Diagnostics showcases new technology at Clinical Lab Expo
Roche Diagnostics is featuring a diverse portfolio of solutions designed to help healthcare facilities and reference labs ... mehr

20. Juli 2009
Xeloda in combination with oxaliplatin shown to be effective in early colon cancer
Roche announced today results from the international phase III study NO16968 (XELOXA), investigating oral Xeloda in combination ... mehr

13. Juli 2009
New data from phase III SATURN study shows Tarceva improves overall survival when used immediately after initial chemotherapy in patients with advanced lung cancer
Roche announced today that SATURN, a pivotal Phase III study, met a key secondary endpoint of extending overall survival in ... mehr

02. Juli 2009
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
Roche announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured ... mehr

01. Juli 2009
Roche launches novel program to ease Tamiflu access to developing economies
Roche today announced the initiation of the Tamiflu Reserves Program (TRP) for developing economies. The program, which is ... mehr

26. Juni 2009
European regulator gives positive opinion for the use of Avastin in combination with docetaxel for the first-line treatment of advanced breast cancer
Physicians will be able to offer patients more Avastin-based treatment options. Patients with advanced (metastatic) breast ... mehr

26. Juni 2009
Roche Files MabThera as a First-line Biologic Treatment for Rheumatoid Arthritis in Europe
Roche announced today that it has submitted a combined filing to the European health authorities (the European Medicines Agency) ... mehr

23. Juni 2009
Roche's Half Year Results for 2009
Roche will publish its Half Year Results for 2009 prior to the opening of the Swiss Stock Exchange on July 23 at 7.00 CET ... mehr

11. Juni 2009
New data demonstrate the ability of MabThera to reduce the progression of joint damage when used as a first-line biologic treatment in rheumatoid arthritis
RA patients with enhanced response identified. New data show for the first time that a course of 2 infusions of MabThera 1000mg ... mehr

11. Juni 2009
Reminder: Roche Investor Science Event: Conference call from EULAR 2009
We are pleased to invite you to a Conference Call to discuss new data on our Rheumatoid Arthritis portfolio being presented ... mehr

11. Juni 2009
Reminder: Invitation to Roche Accounting Teleconference
We are pleased to invite you to an accounting conference call followed by Q&A on the impact of the Genentech transaction ... mehr

10. Juni 2009
New data reinforces long-term efficacy of ACTEMRA in rheumatoid arthritis across all patient population types
Up to 56% of patients with active rheumatoid arthritis (RA) treated with ACTEMRA (tocilizumab, known as RoACTEMRA within the ... mehr

09. Juni 2009
Roche to commence phase III trials with innovative treatment designed to lower cardiovascular risk in diabetes patients with recent heart attack
Roche today announced it will start Phase III clinical investigations for aleglitazar, its innovative PPAR co-agonist R1439 ... mehr

08. Juni 2009
Invitation to Roche Accounting Teleconference
We are pleased to invite you to an accounting conference call followed by Q&A on the impact of the Genentech transaction ... mehr

05. Juni 2009
Reminder: Roche investor science event from ADA 2009
We kindly invite investors and analysts to participate in a conference call that will be held during the American Diabetes ... mehr

02. Juni 2009
IMPACT study shows longer Valcyte treatment provides better protection against cytomegalovirus (CMV) disease
New Phase III study results presented for the first time today at the ninth annual American Transplant Congress 2009 (ATC) ... mehr

01. Juni 2009
Encouraging first data on new targeted treatment for patients with melanoma - the deadliest form of skin cancer
Roche announced today results from a phase I study with PLX4032 (R7204) a new, highly selective and promising treatment for ... mehr

31. Mai 2009
Herceptin landmark study (ToGA) reveals unprecedented survival benefit in HER2-positive stomach cancer
Data from the ToGA study presented today at the American Society for Clinical Oncology Annual Meeting in Orlando, Florida ... mehr

30. Mai 2009
Phase III study showed patients lived longer without advanced lung cancer progressing when Tarceva was added to Avastin as first-line maintenance therapy
Roche today announced that a Phase III study (ATLAS) showed patients with advanced non-small cell lung cancer (NSCLC) who ... mehr

30. Mai 2009
Full results from first Phase III study of Avastin in adjuvant colon cancer announced
Results suggest future trials may hold promise for Avastin as early-stage colon cancer treatment even though C-08 study does ... mehr

28. Mai 2009
New form of targeted therapy offers further hope to patients with advanced HER2-positive breast cancer
Final results from a phase II study presented at ASCO show that 25% of women with advanced HER2-positive breast cancer experienced ... mehr

27. Mai 2009
Reminder: Roche investor science event from ADA 2009
Phase II data on PPAR co-agonist aleglitazar and overall update on Roche´s diabetes & metabolic diseases pipeline mehr

26. Mai 2009
Roche Investor Science Event: Conference call from EULAR 2009
We are pleased to invite you to a Conference Call to discuss new data on our Rheumatoid Arthritis portfolio being presented ... mehr

25. Mai 2009
Reminder - Roche Investor Events: ASCO 2009
We are pleased to invite you to two analyst briefings to discuss data presented on the Roche Group’s oncology products ... mehr

25. Mai 2009
Two-year data reinforce effectiveness of ACTEMRA in inhibiting joint damage and improving physical function in patients with rheumatoid arthritis
Roche announced today that new two-year data from the LITHE study demonstrate that ACTEMRA (tocilizumab, known as RoACTEMRA ... mehr

20. Mai 2009
Roche ASCO planner
Roche and Genentech will present a large number of abstracts on their broad oncology portfolio at the Annual Meeting of American ... mehr

19. Mai 2009
Genentech and Biogen Idec submit applications to the FDA for Rituxan for most common type of adult leukemia
Genentech, Inc., wholly owned member of the Roche Group (SWX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) today ... mehr

19. Mai 2009
Roche Investor Events: ASCO 2009
We are pleased to invite you to two analyst briefings to discuss data presented on the Roche Group’s oncology products ... mehr

18. Mai 2009
Roche joins forces to innovate toxicity testing and to reduce animal experimentation
Today, Roche opened the Joint Science & Technology Laboratory in Basel, where Roche Pharma scientists are using the innovative ... mehr

15. Mai 2009
Avastin plus commonly used chemotherapies improved progression-free survival in advanced breast cancer
Data from RIBBON 1 study provides efficacy and safety information with different types of chemotherapy mehr

15. Mai 2009
Roche to present major advances with targeted cancer medicines at ASCO
More than 500 scientific abstracts to be presented across 20 types of cancers. Results could significantly improve the way ... mehr

11. Mai 2009
Roche investor science event from ADA 2009
Phase II data on PPAR co-agonist aleglitazar and overall update on Roche's diabetes & metabolic diseases pipeline mehr

06. Mai 2009
Important New Treatment Option Approved in US for Patients with the Most Aggressive Form of Brain Cancer
Roche today announced that the US Food and Drug Administration (FDA) granted accelerated approval of Avastin (bevacizumab) ... mehr

04. Mai 2009
Roche Investor Events: ASCO 2009
We are pleased to invite you to two analyst briefings to discuss data presented on the Roche Group’s oncology products ... mehr

30. April 2009
Roche responds to WHO move to influenza pandemic alert phase 5
Roche tonight confirms that it has been in contact with the World Health Organization (WHO) following the announcement to ... mehr

27. April 2009
Ground-breaking combination of all-oral agents demonstrates potential as hepatitis C treatment regimen
Roche (SWX: RO, ROG; OTCQX: RHHBY), InterMune, Inc. (Nasdaq: ITMN) and Pharmasset (Nasdaq: VRUS) announced the first results ... mehr

22. April 2009
Phase III C-08 study of Avastin in early-stage colon cancer does not meet primary endpoint
Roche today announced the results of the first phase III trial evaluating the use of Avastin (bevacizumab) plus chemotherapy ... mehr

16. April 2009
Roche strongly outperforms market in first quarter
Genentech transaction completed, integration proceeding rapidly mehr

15. April 2009
Reminder: Roche's First Quarter Sales 2009 Conference Call
Roche will publish its Sales Results for the 1st Quarter of 2009 prior to the opening of the Swiss Stock Exchange on Thursday ... mehr

15. April 2009
Roche Diabetes Care supports "Changing Diabetes in Children"
Roche today announced that it will join forces with Novo Nordisk and the World Diabetes Foundation (WDF) in Novo Nordisk’s ... mehr

14. April 2009
Roche and Genentech announce organizational and leadership decisions
Following the completion of the Genentech transaction Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) today announced the successful ... mehr

08. April 2009
Roche and Genentech announce voluntary withdrawal of Raptiva from the U.S. market
Roche and Genentech, Inc. announced today a phased voluntary withdrawal of the psoriasis drug Raptiva (efalizumab) from the ... mehr

07. April 2009
Presentational changes of Roche's quarterly sales results
As announced earlier, the Roche Group will publish its first quarter sales results on 16 April 2009. To reflect the Pharmaceuticals ... mehr

02. April 2009
Roche to introduce new LightCycler MRSA Advanced Test in the EU
Roche announced today that its new LightCycler test for the detection of methicillin-resistant Staphylococcus aureus (MRSA) ... mehr

01. April 2009
FDA ADVISORY COMMITTEE UNANIMOUSLY RECOMMENDS ACCELERATED APPROVAL OF AVASTIN FOR PREVIOUSLY TREATED BRAIN CANCER (GLIOBLASTOMA)
Genentech, Inc. announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) ... mehr

31. März 2009
Avastin label updated reflecting confidence in safety profile
The European Medicines Agency (EMEA) has removed a restriction in the product label which prevented the use of Avastin (bevacizumab) ... mehr

26. März 2009
Roche completes acquisition of Genentech
Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) and Genentech announced today that Roche has completed its acquisition of Genentech ... mehr

26. März 2009
Roche completes tender offer for Genentech
Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) announced today that its wholly-owned subsidiary, Roche Investments USA Inc., completed ... mehr

24. März 2009
RiskMetrics Group Recommends Genentech Shareholders Accept Roche's $95.00 per Share Cash Tender Offer
Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) announced today that RiskMetrics Group, Inc., a leading provider of risk and corporate ... mehr

19. März 2009
Roche announces filing of Tarceva in EU as first-line maintenance therapy in advanced non-small cell lung cancer
Today, Roche submitted an extension of the Marketing Authorisation Application to the European Medicines Agency (EMEA) for ... mehr

18. März 2009
Roche's First Quarter Sales 2009 Conference Call
Roche will publish its Sales Results for the 1st Quarter of 2009 prior to the opening of the Swiss Stock Exchange on Thursday ... mehr

18. März 2009
Herceptin now shown to significantly prolong the lives of patients with HER2-positive advanced stomach cancer
Roche today announced results from a major international study which show that adding Herceptin (trastuzumab) to standard ... mehr

12. März 2009
Roche and Genentech reach a friendly agreement to combine the two organizations and create a leader in healthcare innovation
Roche (SWX: ROG.VX; RO.S) and Genentech (NYSE: DNA) announced today that they signed a merger agreement under which Roche ... mehr

11. März 2009
Herceptin proven to benefit women with HER2 positive early breast cancer - latest results from the HERA study
The Breast International Group (BIG) in collaboration with Roche announced today that women with HER2 positive early breast ... mehr

10. März 2009
Roche Annual General Meeting: dividend raised by 9 percent
Roche's Annual General Meeting, which was held today in Basel, has approved all the Board of Directors' proposals. ... mehr

06. März 2009
Roche increases offer price for Genentech shares to US$ 93 per share and extends offer
Roche (SWX: ROG.VX; RO.S) announced today that it has increased its offer price for all outstanding publicly-held shares of ... mehr

27. Februar 2009
Roche announces bond offerings
Roche has successfully undertaken a large offering of notes in U.S. dollars, and is completing another large offering of notes ... mehr

27. Februar 2009
MabThera approved in the EU for patients with chronic lymphocytic leukaemia
Roche announced today that the European Commission has approved MabThera (rituximab) in combination with chemotherapy for ... mehr

16. Februar 2009
Study proves longer prophylactic therapy with Valcyte increases protection against CMV - the most serious viral infection affecting transplant patients
Roche announced today that a Phase III study investigating the efficacy and safety of extended preventative therapy ('prophylaxis') ... mehr

16. Februar 2009
For the first time, doctors can predict which hepatitis B patients have the highest chance to achieve treatment success with Pegasys
New data presented today showed that, for the first time, doctors can predict which hepatitis B patients treated with Pegasys ... mehr

09. Februar 2009
Roche commences tender offer for Genentech for US$86.50 per share in cash
Roche announced today that it is commencing a cash tender offer for all outstanding publicly-held shares of Genentech for ... mehr

04. Februar 2009
Strong operating results for Roche in 2008
Double-digit sales growth – Core Earnings per share at constant exchange rates above 2007 level – Dividend increase ... mehr

03. Februar 2009
Reminder: Roche's Full Year Results for 2008
Roche will publish its Full Year Results for 2008 prior to the opening of the Swiss Stock Exchange on February 4 at 7.00 CET ... mehr

03. Februar 2009
Avastin and Tarceva in combination significantly improves the time patients with advanced lung cancer can live without their disease worsening
Roche today announced interim results from a phase III study (ATLAS) in patients with advanced non small cell lung cancer ... mehr

30. Januar 2009
Roche intends to commence tender offer to acquire all shares of Genentech for US$ 86.50 per share in cash
Roche announced today that it intends to commence a cash tender offer for all outstanding publicly-held shares of Genentech ... mehr

28. Januar 2009
Roche delighted about pool extension
Roche’s Board of Directors and Corporate Executive Committee is delighted about the extension of the shareholders’ ... mehr

28. Januar 2009
MabThera filed in the EU for treatment of relapsed or refractory chronic lymphocytic leukaemia
Roche today announced it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) ... mehr

23. Januar 2009
MabThera receives positive opinion in Europe for first-line treatment for chronic lymphocytic leukaemia
Roche announced today that the European Union’s Committee on Human Medicinal Products (CHMP) has issued a positive recommendation ... mehr

21. Januar 2009
Reminder: Roche's Full Year Results for 2008
Roche will publish its Full Year Results for 2008 prior to the opening of the Swiss Stock Exchange on February 4 at 7.00 ... mehr

21. Januar 2009
RoACTEMRA approved in Europe to treat patients suffering from Rheumatoid Arthritis
Roche today announced that the European Commission has approved RoACTEMRA (tocilizumab, known as Actemra outside of the EU), ... mehr

05. Januar 2009
Roche's Full Year Results for 2008
4 February – 8.00 CET – Morning Telephone Conference 4 February - 15.00 GMT - Presentation in London (16.00 CET) 6 ... mehr

05. Januar 2009
Roche Purchases Shares in Tender Offer for Memory Pharmaceuticals Corp.
Roche (SWX: ROG.VX; RO.S; OTCQX; RHHBY) today announced that its wholly-owned subsidiary 900 North Point Acquisition Corporation ... mehr